Expanding the strategic power of manufacturing execution systems in pharma

Manufacturing execution system needs to do more than go live

Manufacturing execution systems (MES) were once seen as tools to keep production on track and meet compliance requirements. But that view is limiting – and comes with a cost.

Breaking out of the post-launch plateau

Many organisations invest heavily in MES implementation, only to see momentum stall after go-live. Why? Because too often, the plan ends at deployment, and success is measured only by technical functionality. Today, that’s not enough. The full value of MES lies in its ability to drive business impact.

Our latest point of view explores the strategies leading pharma companies are using to make MES a true strategic advantage – closing the post-launch gap and unlocking MES’s full potential.